Integrated Biomarker Analysis Reveals L1CAM as a Potential Stratification Marker for No Specific Molecular Profile High-Risk Endometrial Carcinoma
Histopathologic assessment of high-risk endometrial cancer (EC) suffers from intersubject variability and poor reproducibility. The pragmatic classification in four molecular subgroups helps to overcome these limits, showing a significant prognostic value. The "no specific molecular profile" (NSMP) is the most heterogeneous EC subgroup, requiring further characterization to better guide its clinical management. DNA sequencing of POLE exonuclease domain and immunohistochemistry for PMS2, MSH6, and p53 were performed in order to stratify a cohort of 94 high-risk EC patients in the four molecular subgroups. Moreover, a panel of seven additional biomarkers was tested. Patients were found to be 16% POLE-mutated, 36% mismatch repair-deficient, 27% p53-abnormal, and 21% NSMP. In the multivariable model, molecular groups confirmed their significant association with disease-specific survival and progression-free survival, with p53-abnormal and NSMP endometrial cancer characterized by poor outcomes. Among the additional evaluated biomarkers, L1CAM was the only one with a significant prognostic value within the NSMP subgroup. NSMP/L1CAM-positive patients experienced the worst outcome and were "early-relapsing" after platinum-based chemotherapy, with a significantly shorter platinum-free interval compared to L1CAM-negative patients. L1CAM appears to be a promising candidate as a prognostic and predictive biomarker in the high-risk NSMP subgroup, which is actually known to lack specific molecular markers.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Cancers - 14(2022), 21 vom: 03. Nov. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ravaggi, Antonella [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
High-risk endometrial carcinoma |
|---|
| Anmerkungen: |
Date Revised 17.11.2022 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/cancers14215429 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM348724314 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM348724314 | ||
| 003 | DE-627 | ||
| 005 | 20231226040930.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/cancers14215429 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1162.xml |
| 035 | |a (DE-627)NLM348724314 | ||
| 035 | |a (NLM)36358847 | ||
| 035 | |a (PII)5429 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ravaggi, Antonella |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Integrated Biomarker Analysis Reveals L1CAM as a Potential Stratification Marker for No Specific Molecular Profile High-Risk Endometrial Carcinoma |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 17.11.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Histopathologic assessment of high-risk endometrial cancer (EC) suffers from intersubject variability and poor reproducibility. The pragmatic classification in four molecular subgroups helps to overcome these limits, showing a significant prognostic value. The "no specific molecular profile" (NSMP) is the most heterogeneous EC subgroup, requiring further characterization to better guide its clinical management. DNA sequencing of POLE exonuclease domain and immunohistochemistry for PMS2, MSH6, and p53 were performed in order to stratify a cohort of 94 high-risk EC patients in the four molecular subgroups. Moreover, a panel of seven additional biomarkers was tested. Patients were found to be 16% POLE-mutated, 36% mismatch repair-deficient, 27% p53-abnormal, and 21% NSMP. In the multivariable model, molecular groups confirmed their significant association with disease-specific survival and progression-free survival, with p53-abnormal and NSMP endometrial cancer characterized by poor outcomes. Among the additional evaluated biomarkers, L1CAM was the only one with a significant prognostic value within the NSMP subgroup. NSMP/L1CAM-positive patients experienced the worst outcome and were "early-relapsing" after platinum-based chemotherapy, with a significantly shorter platinum-free interval compared to L1CAM-negative patients. L1CAM appears to be a promising candidate as a prognostic and predictive biomarker in the high-risk NSMP subgroup, which is actually known to lack specific molecular markers | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a L1CAM | |
| 650 | 4 | |a NSMP | |
| 650 | 4 | |a high-risk endometrial carcinoma | |
| 650 | 4 | |a molecular classification | |
| 650 | 4 | |a platinum-based adjuvant chemotherapy | |
| 650 | 4 | |a prognosis | |
| 700 | 1 | |a Capoferri, Davide |e verfasserin |4 aut | |
| 700 | 1 | |a Ardighieri, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Ghini, Iacopo |e verfasserin |4 aut | |
| 700 | 1 | |a Ferrari, Federico |e verfasserin |4 aut | |
| 700 | 1 | |a Romani, Chiara |e verfasserin |4 aut | |
| 700 | 1 | |a Bugatti, Mattia |e verfasserin |4 aut | |
| 700 | 1 | |a Zanotti, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Vrede, Stephanie |e verfasserin |4 aut | |
| 700 | 1 | |a Tognon, Germana |e verfasserin |4 aut | |
| 700 | 1 | |a Pijnenborg, Johanna M A |e verfasserin |4 aut | |
| 700 | 1 | |a Sartori, Enrico |e verfasserin |4 aut | |
| 700 | 1 | |a Calza, Stefano |e verfasserin |4 aut | |
| 700 | 1 | |a Bignotti, Eliana |e verfasserin |4 aut | |
| 700 | 1 | |a Odicino, Franco |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancers |d 2009 |g 14(2022), 21 vom: 03. Nov. |w (DE-627)NLM198667213 |x 2072-6694 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2022 |g number:21 |g day:03 |g month:11 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/cancers14215429 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2022 |e 21 |b 03 |c 11 | ||